The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular characteristics and clinical outcomes of breast cancer with HRAS mutations.
 
Samuel Kareff
No Relationships to Disclose
 
Estelamari Rodriguez
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Janssen Oncology; Novartis; Oncocyte; Research to Practice
 
Richa Dawar
Honoraria - Agendia; Bayer; Targeted Oncology
Consulting or Advisory Role - Agendia; Daiichi Sankyo; Onc Live; Targeted Oncology
 
Asaad Trabolsi
No Relationships to Disclose
 
Jesus Antonio Ocejo Gallegos
No Relationships to Disclose
 
Jun Yin
No Relationships to Disclose
 
Phillip Walker
Employment - Caris Life Sciences
 
Irene Kang
Honoraria - Bristol Myer Squibb; Puma Biotechnology
Speakers' Bureau - Puma Biotechnology
 
Matias A. Bustos
No Relationships to Disclose
 
Josh Neman
No Relationships to Disclose
 
Dave S. Hoon
Stock and Other Ownership Interests - Biological Dynamics; Clearbridge Biomedics; Guardant Health
Honoraria - Archer; Castle Biosciences; Invitae
Consulting or Advisory Role - Archer; Castle Biosciences; Chrysalis Biomedical Advisors; Invitae
Speakers' Bureau - CHI Pharma; Oxford Gene Technology
Research Funding - Merck
 
Stephanie L. Graff
Stock and Other Ownership Interests - HCA Healthcare
Honoraria - Publicis Health
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Genentech; Novartis; Novartis (Inst); Pfizer; Seagen (Inst)
Speakers' Bureau - OncLive
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Eisai (Inst); Foundation Medicine (Inst); Genentech (Inst); GRAIL (Inst); H3 Biomedicine (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Polyphor (Inst); Roche (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst)
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences
 
Gilberto Lopes
Stock and Other Ownership Interests - Lucence Diagnostics; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics